
1. Cell Stem Cell. 2019 Nov 7;25(5):607-621.e7. doi: 10.1016/j.stem.2019.08.016.
Epub 2019 Sep 19.

NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects
Mutations in HSPCs from Patients with Fanconi Anemia.

Román-Rodríguez FJ(1), Ugalde L(1), Álvarez L(1), Díez B(1), Ramírez MJ(2),
Risueño C(1), Cortón M(3), Bogliolo M(2), Bernal S(4), March F(5), Ayuso C(3),
Hanenberg H(6), Sevilla J(7), Rodríguez-Perales S(8), Torres-Ruiz R(9), Surrallés
J(2), Bueren JA(1), Río P(10).

Author information: 
(1)Division of Hematopoietic Innovative Therapies, Centro de Investigaciones
Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro
de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 
28040, Spain; Advanced Therapies Unit, Instituto de Investigación Sanitaria
Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid 28040, Spain.
(2)Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER-ISCIII), Madrid 28040, Spain; Genome Instability and DNA Repair
Syndromes Group, Department of Genetics and Microbiology, Universitat Autònoma de
Barcelona (UAB), Barcelona 08193, Spain; Servicio de Genética e Instituto de
Investigaciones Biomédicas del Hospital de Sant Pau, Barcelona 08025, Spain.
(3)Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER-ISCIII), Madrid 28040, Spain; Department of Genetics, Hospital
Universitario Instituto de Investigación Sanitaria Fundación Jiménez Díaz
(IIS-FJD, UAM), Madrid 28040, Spain.
(4)Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER-ISCIII), Madrid 28040, Spain; Servicio de Genética e Instituto de
Investigaciones Biomédicas del Hospital de Sant Pau, Barcelona 08025, Spain.
(5)Servicio de Genética e Instituto de Investigaciones Biomédicas del Hospital de
Sant Pau, Barcelona 08025, Spain.
(6)Department of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine
University, Düsseldorf 40225, Germany; Department of Pediatrics III, University
Children's Hospital Essen, University of Duisburg-Essen, Essen 45122, Germany.
(7)Hospital Universitario Niño Jesús, Madrid 28009, Spain.
(8)Molecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional
de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain.
(9)Molecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional
de Investigaciones Oncológicas (CNIO), Madrid 28029, Spain; Josep Carreras
Leukemia Research Institute and Department of Biomedicine, School of Medicine,
University of Barcelona, Barcelona 08036, Spain.
(10)Division of Hematopoietic Innovative Therapies, Centro de Investigaciones
Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain; Centro
de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid 
28040, Spain; Advanced Therapies Unit, Instituto de Investigación Sanitaria
Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid 28040, Spain. Electronic address:
paula.rio@ciemat.es.

Comment in
    Cell Stem Cell. 2019 Nov 7;25(5):592-593.

Non-homologous end-joining (NHEJ) is the preferred mechanism used by
hematopoietic stem cells (HSCs) to repair double-stranded DNA breaks and is
particularly increased in cells deficient in the Fanconi anemia (FA) pathway.
Here, we show feasible correction of compromised functional phenotypes in
hematopoietic cells from multiple FA complementation groups, including FA-A,
FA-C, FA-D1, and FA-D2. NHEJ-mediated repair of targeted CRISPR-Cas9-induced DNA 
breaks generated compensatory insertions and deletions that restore the coding
frame of the mutated gene. NHEJ-mediated editing efficacy was initially verified 
in FA lymphoblastic cell lines and then in primary FA patient-derived CD34+
cells, which showed marked proliferative advantage and phenotypic correction both
in vitro and after transplantation. Importantly, and in contrast to homologous
directed repair, NHEJ efficiently targeted primitive human HSCs, indicating that 
NHEJ editing approaches may constitute a sound alternative for editing
self-renewing human HSCs and consequently for treatment of FA and other monogenic
diseases affecting the hematopoietic system.

Copyright © 2019 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.stem.2019.08.016 
PMID: 31543367  [Indexed for MEDLINE]

